The CDC has yet again released a report highlighting the growing HIV disparity in young, black men who have sex with men (MSM). Over a decade ago, similar attention was called to what then appeared to be a public health blemish in this population. Because our prevention efforts have been largely cosmetic and woefully inadequate, the 7% increase in the infection rate among black MSM suggests this blemish is now a gushing and gaping wound requiring urgent public health action.
The effects of HIV and highly active antiretroviral therapy [HAART] on gut health were highlighted recently at the 13th International Workshop on Adverse Drug Reactions and Co-Morbidities in HIV in Rome, Italy.
The pending HIV legislation is much on my mind these days, for reasons I outlined here. Bottom line is that I don't think it's good for patient care, and we're missing a real opportunity to make things better here in the Bay State.
One famous HIV clinician/clinical researcher likens co-formulated TDF/FTC/EFV (Atripla) to a "Godzilla," so dominant has the treatment become as initial therapy for HIV. He bases his comments on this study done at his institution, showing that in 2007, fully 85% of patients starting treatment in their clinic began TDF/FTC/EFV.
First, there's the requirement for written informed consent, something that every state (except a couple) has wisely abandoned. Second, it's more than a testing law -- it's also an HIV privacy law, which is arguably unnecessary in this post HIPAA era and has all sorts of unintended consequences.
Just back from IAS 2011 (which was followed, I'm thrilled to say, with a visit to perhaps the most beautiful region in the world). Here is a Really Rapid ReviewTM of the meeting, with apologies ahead of time for lack of organization and (even more likely) leaving out something important. FYI, the abstracts are online here; I'm sure there's a place on the meeting homepage that has the same link, but I can't seem to find it.
Groundbreaking results of two large pre-exposure prophylaxis (PrEP) studies may lead to a new prevention option to reduce HIV transmission. Data released on two PrEP studies showed high levels of protection against HIV infection when tenofovir (Viread) or Truvada (tenofovir and emtricitabine) were taken daily by HIV-uninfected individuals at high risk for infection.
In my current practice, every day there is at least one man over the age of 50 asking for an erectile dysfunction (ED) medication. It seems to have become an epidemic. Or it is just more openly discussed. Or both.
As part of the usual flurry of studies released just before major scientific meetings, results of two pre-exposure prophylaxis (PrEP) trials in heterosexual men and women have just been made public:
The result of the above stellar behavior? I would do virtually anything to try and help her. Back in the late 1990s, when she was very sick with AIDS, one of my fellows said it best: "There's just something about her that makes you want to take care of her." Exactly.